Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
INS-IGF2
REST API REST API
Homo sapiens
INS-IGF2 is differentially expressed in 154 experiments: 119 organism parts: liver, placenta, ... (117 more);, 114 disease states: normal, prostate carcinoma, ... (112 more);, 48 cell types 201 cell lines 15 compound treatments and 57 other conditions.
Orthologs insb (Danio rerio)   INS_CHICK (Gallus gallus)   ins (Danio rerio)   F1LYE5_RAT (Rattus norvegicus)   ins (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term extracellular region, hormone activity
InterPro Term Insulin-like, Insulin
UniProt Accession F8WCM5
Search EB-eye ENSG00000129965
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-1880, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, ... (18 experiments)

Factor Value U/D Experiments
LS174T
1
E-MTAB-37
Hep-2
1
E-MTAB-62
MT3
1
E-MTAB-37
MCIXC
1
E-MTAB-37
NCIH82
1
E-MTAB-37
SCH
1
E-GEOD-15460
195 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13987, ... (28 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
CD71+ early erythroid
1
E-AFMX-5
CD8+ T cell
1
E-AFMX-5
leydig cell
1
E-MTAB-25
lung carcinoma
1
E-GEOD-17347
42 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-3744, E-GEOD-2466, E-GEOD-1869, ... (23 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-7307
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
non-ischemic cardiomyopathy
1
E-GEOD-1869
tumor
1
E-GEOD-19188
adenocarcinoma
1
E-MTAB-62
108 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-2067, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, ... (11 experiments)

Factor Value U/D Experiments
none
1
3
E-GEOD-4600, E-GEOD-412, E-GEOD-7400, E-GEOD-2803
glutamine
2
E-MEXP-1335, E-MEXP-941
hepatitis C virus core protein
1
E-GEOD-2067
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
phorbol 12-myristate 13-acetate
1
E-GEOD-4600
bacterial endotoxin
1
1
E-GEOD-3284
9 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-4667, E-TABM-145, E-MTAB-62 ... (5 experiments)

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-2152, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-601, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-215, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-6919, E-GEOD-16363, ... (19 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-TABM-130, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Phenotype
studied in E-GEOD-1657, E-GEOD-4600

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-1343

Replicate
studied in E-GEOD-19330

RNAi
studied in E-MEXP-2115, E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.516 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM